



Express Mail Mailing Label No. EV457083272US

PATENT  
Attorney Docket No. MTP-024

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Watkins *et al.*  
SERIAL NO.: 09/709,947 GROUP NO.: 1642  
FILING DATE: November 10, 2000 EXAMINER: Harris, Alana M.  
TITLE: Materials and Methods for Detection and Treatment of Breast Cancer

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the patents and publications are enclosed.

REMARKS


In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- ☒ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☐ (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and
- ☐ the requisite Statement is below, **OR**
- ☐ the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or

- ☐ (3) after the mailing date of a **final action** or **notice of allowance** but before the payment of the **issue fee**, **AND**
- ☐ the requisite Statement is below, **AND**
- ☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

Respectfully submitted,




Brian Fairchild, Ph.D.  
Attorney for Applicant(s)  
Testa, Hurwitz, & Thibeault, LLP  
High Street Tower  
125 High Street  
Boston, Massachusetts 02110

Date: December 14, 2004  
Reg. No. 48,645

Tel. No.: (617) 248-7697  
Fax No.: (617) 248-7100

3155831\_1



Express Mail Mailing Label No. EV457083272US

SHEET 1 OF 1

<b>FORM PTO - 1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>				ATTORNEY DOCKET NO.: MTP-024 APPLICANT(S): Watkins et al. SERIAL NO.: 09/709,947 FILING DATE: November 10, 2000      GROUP: 1642					
<b>U.S. PATENT DOCUMENTS</b>									
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
<b>FOREIGN PATENT DOCUMENTS</b>									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
<b>OTHER ART, JOURNAL ARTICLES, ETC.</b>									
EXAM. INIT.	<b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>								
	C1	Bringmann <i>et al.</i> , (1983) "5'-Terminal Caps of snRNAs Are Accessible for Reaction with 2,2,7-Trimethylguanosine-specific Antibody in Intact snRNPs*," <u>J. Biol. Chem.</u> , 258(5): 2745-2747.							
	C2	Brown <i>et al.</i> , (2001) "Hypoxia and oxidative stress in breast cancer: Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer," <u>Breast Cancer Res.</u> , 3(5): 323-327.							
	C3	Casciola-Rosen <i>et al.</i> , (1994) "Autoantigens Targeted in Systemic Lupus Erythematosus Are Clustered in Two Populations of Surface structures on Apoptotic Keratinocytes," <u>J. Exp. Med.</u> , 179: 1317-1330.							
	C4	Craft <i>et al.</i> , (1988) "The U2 Small Nuclear Ribonucleoprotein Particle as an Autoantigen: Analysis with Sera from Patients with Overlap Syndromes," <u>J. Clin. Invest.</u> , 81: 1716-1724.							
	C5	El-Hefnawy <i>et al.</i> , (2004) "Characterization of Amplifiable, Circulating RNA in Plasma and its Potential as a Tool for Cancer Diagnostics," <u>Clin. Chem.</u> , 50(3): 564-573.							
	C6	Ochs <i>et al.</i> , (1994) "Coiled bodies in the nucleolus of breast cancer cells," <u>J. Cell Sci.</u> , 107: 385-399.							
	C7	Utz, <i>et al.</i> , (2000) "Death, autoantigen modifications, and tolerance," <u>Arthritis Res.</u> , 2:101-114.							
	C8	Will <i>et al.</i> , (2002) "Characterization of novel SF3B and 17S U2 snRNP proteins, including a human Prp5p homologue and SF3b DEAD-box protein," <u>EMBO J.</u> , 21: 4978-4988.							
<b>EXAMINER</b>					<b>DATE CONSIDERED</b>				

3155841\_1